A Single Peptide Restored Gut Barrier and Reset Aging Immune Cells in Mice

If you've ever wondered why gut trouble seems to compound with age, and why that seems to ripple outward into so much else, a new mouse study offers a concrete biological reason. Researchers at North Dakota State University found that a single naturally occurring peptide can reopen a communication channel between the aging gut and the bone marrow, the factory that produces the body's immune cells. Restoring that channel repaired the gut lining, rebalanced the gut microbiome, and calmed the kind of low-grade inflammation that scientists increasingly link to the diseases of old age.

Key takeaways

• A natural peptide called alamandine, acting through a receptor called MrgD, reversed leaky gut and restored a healthier gut microbiome in aged mice.
• It also reset an aging-related imbalance in bone marrow immune cells, shifting them from an inflammatory state back toward a calmer one.
• The gut and the bone marrow's immune cell factory appear to be in constant chemical conversation, and aging seems to corrupt that conversation.
• This was tested only in mice using a surgically implanted pump, with modest group sizes (4 to 7 mice per group), so it is a promising mechanism, not a human treatment.

Alamandine Activates MrgD to Reverse Leaky Gut

A peptide called alamandine (Ala), a signaling molecule in the renin-angiotensin system (RAS, a hormone network best known for controlling blood pressure), reversed age-related leakiness in the intestinal wall of mice by acting on a receptor called MrgD (Mas-related G protein-coupled receptor, member D), according to a study published in the British Journal of Pharmacology. Alamandine was first identified just over a decade ago and has mostly been studied in the heart and blood vessels; this is the first look at what it does in the aging gut.

The researchers measured intestinal permeability, commonly called "leaky gut," using a dye called FITC-dextran that should stay inside the gut if the barrier is intact. In old mice, the dye leaked into the bloodstream at every time point tested; treating old mice with alamandine reversed that leakiness in both males and females (P < 0.0001). The same pattern showed up in a blood marker called LPS-binding protein (LBP), which rises when gut bacteria leak across a damaged barrier: it was elevated in old mice and dropped significantly after alamandine treatment.

The mechanism traces back to intestinal stem cells (ISCs), the cells that continuously rebuild the gut lining. MrgD sits on these stem cells, and its levels dropped in the colons of aging male mice. In colon organoids (miniature lab-grown replicas of gut tissue) derived from old mice, alamandine restored a growth signal called Wnt3a that ISCs need to divide and repair the barrier. Blocking the receptor's downstream signaling chain, an enzyme cascade running through Gαs, adenylyl cyclase and a protein called CREB, erased the effect, tying the repair directly back to MrgD.

Aging Inflammation Ties Back to Chronic Disease Risk

The kind of chronic, low-grade inflammation this study targets, often called "inflammaging," has been described elsewhere as a hallmark of aging across species, and researchers have connected a leaky gut to conditions such as IBS, IBD, depression and cardiovascular disease. That makes a gut-level repair mechanism relevant well beyond digestion. If a leaky gut helps drive the low-grade inflammation seen in aging bodies more broadly, a way to reseal it could matter to anyone researching a gut-brain or gut-immune link behind a condition they are managing, from mood changes to joint or autoimmune symptoms.

How Researchers Tested Alamandine in Aging Mice

The team compared young mice (3 to 4 months old) with old mice (22 to 24 months old), delivering alamandine continuously through a surgically implanted osmotic pump for four weeks. They then measured gut permeability, stem cell and barrier protein levels, gut bacteria composition via 16S rRNA sequencing, immune cell populations in the colon and bone marrow via flow cytometry, and levels of bacterial metabolites in the gut and blood. Most experimental groups included 5 or more mice, though some early dose-finding work used only 4 mice per group and the authors flagged those results as preliminary.

What the Gut-Bone Marrow Signal Could Mean for Aging

Restoring the gut barrier came with a broader reset of the gut-bone marrow axis, the communication line between gut bacteria and the immune cells the bone marrow produces. The gut microbiome of old mice showed lower bacterial diversity and a shifted ratio between two dominant bacterial groups, Bacillota and Bacteroidota, both of which alamandine partially restored. In the colon, old mice had more pro-inflammatory (CD80-positive) macrophages and fewer anti-inflammatory (CX3CR1-positive) ones; alamandine reversed that balance. A similar aging signature, more inflammatory monocytes and macrophages and fewer calming ones, showed up in the bone marrow itself, and alamandine shifted that balance back too.

The most striking test involved transferring fluid extracted from the gut contents of old mice directly onto bone marrow cells from young mice: that fluid alone was enough to push the young marrow cells toward producing more monocytes and inflammatory macrophages. Fluid from alamandine-treated old mice did not have that effect. That is a direct demonstration that chemical signals from an aging gut can reach the bone marrow and reprogram it, independent of any nerve or blood vessel connection.

None of this means a leaky-gut supplement or fix is proven or available. Alamandine here was delivered by an implanted pump directly into mice, not swallowed as a pill, and no human dosing or safety data exist. What the study does offer is a concrete biological reason to take the gut-immune-aging connection seriously if you are already researching it, and a specific pathway, alamandine and MrgD, for future studies to test.

Limitations: Small Mouse Groups and No Human Data Yet

This is a mouse-only mechanistic study, and several of its most novel measurements relied on modest group sizes, roughly 4 to 7 mice per group. The authors themselves note the study has other limits: alamandine was delivered through a surgically implanted pump rather than an oral formulation that would be clinically practical, no measurements were taken of how much alamandine actually reached the bloodstream or tissues, and the gut microbiome was compared across separate groups of mice at a single end point rather than tracked in the same animals over time. There is no evidence yet that this pathway behaves the same way in human aging.

Next Steps for Oral Alamandine and Human Studies

The authors point to prior work showing an oral, cyclodextrin-based formulation of alamandine has been tested in other rodent studies, suggesting a pill form is at least plausible for future research. From here, the logical next steps are pharmacokinetic studies tracking alamandine levels in blood and tissue, microbiome tracking within the same animals over time, and eventually testing whether the same MrgD-dependent repair mechanism holds up in human gut tissue. No timeline for human studies was given.

Common Questions

What is alamandine and how does it relate to blood pressure? Alamandine is part of the renin-angiotensin system, the same hormone network targeted by common blood pressure medications, but it works through a separate, more recently identified receptor called MrgD rather than the classic angiotensin receptors those drugs target.

Does this mean a supplement can fix leaky gut and aging inflammation? No. Alamandine was delivered by a surgically implanted pump directly into mice, not as an oral supplement, and there is no approved human product, dose, or safety data, so there is nothing here to try.

What is the gut-bone marrow axis? It is the chemical communication line between gut bacteria and the bone marrow, where blood and immune cells are made; signals from the gut can steer the bone marrow toward producing more inflammatory immune cells, a process this study found is amplified by aging and reversible with alamandine in mice.

Could this eventually help with IBS, IBD, or other digestive conditions? It is too early to say. This study focused on natural aging rather than a specific digestive disease, but its core finding, that repairing the gut barrier and rebalancing gut bacteria calms inflammation, is the kind of mechanism future studies on IBD, IBS, or other gut-linked conditions would need to test directly.

References

1. Kishore Chittimalli, Henryata E. Rozario, Victor Martinez, et al. (2026). Alamandine/MrgD pathway modulates gut–bone marrow axis in ageing. British Journal of Pharmacology. https://doi.org/10.1111/bph.70656
2. Anna M. Salazar, Ricardo Aparicio, Rebecca I. Clark, Michael Rera, David W. Walker (2023). Intestinal barrier dysfunction: an evolutionarily conserved hallmark of aging. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.049969